Results 101 to 110 of about 5,026 (198)

Chimeric Antigen Receptor T‐Cells in Myasthenia Gravis: Advances, Safety Challenges, and Future Directions

Muscle &Nerve, Volume 73, Issue 6, Page 942-951, June 2026.
ABSTRACT This review examines the emerging application of chimeric antigen receptor (CAR) T‐cell therapy in myasthenia gravis (MG), with emphasis on safety, efficacy signals, and future therapeutic potential in treatment‐refractory disease. A comprehensive literature search was conducted across PubMed, medRxiv, bioRxiv, and Google Scholar for studies ...
Tobias Hegelmaier, Alexander Duscha, Christiane Desel, Sarah Stassen, Tim Krzemien, Ann‐Katrin Hennemann, Vaia Pappa, Aiden Haghikia   +7 more
wiley   +1 more source

In‐Depth Profiling Highlights the Effect of Efgartigimod on Peripheral Innate and Adaptive Immune Cells in Myasthenia Gravis

Annals of Clinical and Translational Neurology, Volume 13, Issue 5, Page 1028-1040, May 2026.
ABSTRACT Background Myasthenia gravis (MG) is an autoimmune disorder characterized by antibody‐mediated complement activation. Efgartigimod, a neonatal Fc receptor (FcRn) antagonist, is approved for treating generalized MG (gMG). However, its modulatory effects on upstream innate and adaptive immune cells remain largely unexplored.
Lei Jin, Liu Dong, Ying Wang, Dingxian He, Chong Yan, Jianying Xi, Haoqin Jiang, Yu Shi, Ming Guan, Chongbo Zhao, Jie Song, Sushan Luo   +11 more
wiley   +1 more source

Open-label study of efgartigimod in seronegative myasthenia gravis

Therapeutic Advances in Neurological Disorders
Background: The ADAPT trial demonstrated the benefit of efgartigimod, a neonatal Fc receptor (FcRn) inhibitor, in acetylcholine receptor antibody (AChRAb) positive patients with generalized myasthenia gravis (MG).
Mohamed Khateb, Ajith Sivadasan, Carolina Barnett-Tapia, Lubna Daniyal, Lahiru Fernando, Shiyi Chen, Leif Erik Lovblom, Hans Katzberg, Vera Bril   +8 more
doaj   +1 more source

Profiling Localized Immunomodulation and Drug Biodistribution within a Subcutaneous Vascularized Niche for Cell Transplantation

Advanced Science, Volume 13, Issue 28, 18 May 2026.
We studied how five common immunosuppressants behave when delivered directly to a transplant site instead of systemically. Using a vascularized implant for islet transplantation, we show that local delivery protects grafts, limits drug spread to the rest of the body, and produces distinct immune signatures.
Jocelyn Nikita Campa‐Carranza, Simone Capuani, Melissa A. Willman, Alexander Rabassa, Ashley L. Joubert, Tommaso Bo, Letizia Franco, Marzia Conte, Ana L. Anaya‐García, Gabrielle E. Rome, Rim Ouni, Henry J. Seaborne, Camden A. Caffey, Dora M. Berman, Junjun Zheng, Jesus Paez‐Mayorga, Corrine Ying Xuan Chua, Shu Hsia Chen, Norma S. Kenyon, Alessandro Grattoni   +19 more
wiley   +1 more source

Clinical outcomes, serum IgG changes, and follow-up observations in the treatment of anti-AChR antibody-positive generalized myasthenia gravis with Efgartigimod

BMC Neurology
Purpose To investigate the clinical effects, changes in serum IgG levels, and follow-up observations following treatment with Efgartigimod in patients with anti-acetylcholine receptor (anti-AChR) positive generalized myasthenia gravis (gMG). Methods This
Jingting Fu, Xianzhao Zheng, Xiaoli Ma, Qianqian Qu, Wenhao Cui, Xing Mao, Wenhua Fu, Haidong Lyv   +7 more
doaj   +1 more source

Ontogeny of Placental FcRn Protein During Human and Animal Pregnancy to Inform Developmental Toxicity Testing

Birth Defects Research, Volume 118, Issue 5, May 2026.
ABSTRACT Introduction Species differences exist in Fc domain‐containing molecule transfer/biodistribution to the embryo‐fetus during pregnancy. Placentation was reviewed and placental neonatal Fc receptor (FcRn) quantitation in the chorioallantoic placenta (CAP) and/or inverted yolk sac placenta (InvYSP) was investigated across species throughout ...
Christopher J. Bowman, William J. Breslin, Connie Chen, Warren Foster, Julia Hui, Beata Kusmider, Susan Laffan, Matt Myers, Lakshmi Sivaraman, Belen Tornesi, Susan Westmoreland, John M. DeSesso   +11 more
wiley   +1 more source

Real-World Experience with FcRn Inhibitors Efgartigimod and Rozanolixizumab in Myasthenia Gravis: Administration in Multiple Cycles and Transition from Intravenous to Subcutaneous Formulation

Neurology and Therapy
The neonatal Fc receptor (FcRn) inhibitors efgartigimod and rozanolixizumab have not long been introduced for treating generalized myasthenia gravis (MG); hence, real-world evidence for their administration in multiple cycles and switching from intravenous to subcutaneous formulation remains insufficient.We retrospectively assessed 17 consecutive ...
Masaaki Yoshikawa, Yukako Inoue, Koya Tanaka, Keisuke Tsumura, Yuki Hoshino, Chika Shichijo, Toshihiro Ide, Kohei Suzuyama, Megumi Iwasaki, Makoto Eriguchi, Motohiro Yukitake, Hiroshi Takashima, Haruki Koike   +12 more
openaire   +3 more sources

Repurpose an FDA‐Approved Antibody Using DARPin‐Scaffolded Bridge Protein

Chemistry–Methods, Volume 6, Issue 5, May 2026.
The cell line and scalable upstream/downstream process development needed for every new monoclonal antibody are both highly expensive and time‐consuming, significantly increasing the cost of new antibody therapeutics. By contrast, the production of many synthetic binders can be accomplished rapidly and with lower production costs.
Michael Woolley, Joshua D. Bryant, Samuel Vrana, Karuppiah Chockalingam, Zhilei Chen   +4 more
wiley   +1 more source

Sustained delivery and molecular targeting of a therapeutic monoclonal antibody to metastases in the central nervous system of mice. [PDF]

, 2019
Approximately 15-40% of all cancers develop metastases in the central nervous system (CNS), yet few therapeutic options exist to treat them. Cancer therapies based on monoclonal antibodies are widely successful, yet have limited efficacy against CNS ...
Chen, Irvin SY, Guan, Xin, Kamata, Masakazu, Kranz, Emiko, Lee, YooJin, Liu, Chaoyong, Liu, Yang, Lu, Yunfeng, Martinez-Maza, Otoniel, Qin, Meng, Sun, Guibo, Sun, Xiaobo, Vinters, Harry V, Wang, Lan, Wen, Jing, Widney, Daniel, Wu, Di, Xu, Duo   +17 more
core  

Factors associated with response to rituximab in patients with immune thrombocytopenia

HemaSphere, Volume 10, Issue 5, May 2026.
Abstract Rituximab is a well‐established treatment for adult immune thrombocytopenia (ITP), with ~60% initial response (IR) and 20%–30% long‐term remissions. We conducted a register‐based cohort study of 759 ITP patients in Sweden, Denmark, and Norway treated with rituximab (2009–2018) to identify factors associated with response.
Galina Tsykunova, Eskild Bendix Kristiansen, Tor Henrik Anderson Tvedt, Henrik Frederiksen, Christian Fynbo Christiansen, Marie Linder, Shahram Bahmanyar, Waleed Ghanima   +7 more
wiley   +1 more source